SCHEMBL3766334

SCHEMBL3766334

C[C@H](NC(=O)c1cccc(NC(=O)c2c(Cl)cccc2Cl)c1)c1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.53
ACKR3 P25106 1/20 0.51
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3778219 1.00 PTGES (0.53) PTGESACKR3LMNAGAATP53
SCHEMBL3768793 0.90 PTGES (0.66) PTGESACKR3LMNA
SCHEMBL3770507 0.90 PTGES (0.66) PTGESACKR3LMNA
SCHEMBL3770566 0.85 MEN1 (0.59) LMNAGAA
SCHEMBL3768954 0.85 MEN1 (0.59) LMNAGAA
SCHEMBL3776657 0.83 KCNK3 (0.56)
SCHEMBL3766322 0.83 KCNK3 (0.56)
SCHEMBL3779790 0.82 MEN1 (0.55) PTGES
SCHEMBL3770521 0.82 F2R (0.55) PTGES
SCHEMBL3777602 0.82 F2R (0.55) PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324086-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2010-12-23 US claimed
WO-2009103778-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2009-08-27 WO claimed
US-20100324086-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324086-A1 COMPOUNDS AND METHODS IL1B, LITAF, CYP11B1 PTGES 54/4885ACKR3 1463/4885LMNA 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.